136 related articles for article (PubMed ID: 26433207)
1. Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Williams KH; Sullivan DR; Veillard AS; O'Brien R; George J; Jenkins AJ; Young S; Ehnholm C; Duffield A; Twigg SM; Keech AC
Diabet Med; 2016 Mar; 33(3):356-64. PubMed ID: 26433207
[TBL] [Abstract][Full Text] [Related]
2. Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Williams KH; Sullivan DR; Nicholson GC; George J; Jenkins AJ; Januszewski AS; Gebski VJ; Manning P; Tan YM; Donoghoe MW; Ehnholm C; Young S; O'Brien R; Buizen L; Twigg SM; Keech AC
Metabolism; 2016 May; 65(5):783-793. PubMed ID: 27085785
[TBL] [Abstract][Full Text] [Related]
3. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
5. Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes.
Afarideh M; Aryan Z; Ghajar A; Noshad S; Nakhjavani M; Baber U; Mechanick JI; Esteghamati A
Atherosclerosis; 2016 Nov; 254():42-51. PubMed ID: 27684605
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population.
Ruhl CE; Everhart JE
Gastroenterology; 2009 Feb; 136(2):477-85.e11. PubMed ID: 19100265
[TBL] [Abstract][Full Text] [Related]
7. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL; Januszewski AS; O'Connell R; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Hung WT; Scott RS; Taskinen MR; Keech AC; Rye KA
Diabetologia; 2015 Mar; 58(3):464-73. PubMed ID: 25425220
[TBL] [Abstract][Full Text] [Related]
8. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study.
Schindhelm RK; Dekker JM; Nijpels G; Bouter LM; Stehouwer CD; Heine RJ; Diamant M
Atherosclerosis; 2007 Apr; 191(2):391-6. PubMed ID: 16682043
[TBL] [Abstract][Full Text] [Related]
9. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study.
Monami M; Bardini G; Lamanna C; Pala L; Cresci B; Francesconi P; Buiatti E; Rotella CM; Mannucci E
Metabolism; 2008 Mar; 57(3):387-92. PubMed ID: 18249212
[TBL] [Abstract][Full Text] [Related]
10. Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver.
Kim CH; Park JY; Lee KU; Kim JH; Kim HK
Diabetes Metab Res Rev; 2009 Jan; 25(1):64-9. PubMed ID: 19065605
[TBL] [Abstract][Full Text] [Related]
11. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL; Januszewski AS; O'Connell R; Buizen L; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Rye KA; Keech AC;
Diabetologia; 2015 Sep; 58(9):2035-44. PubMed ID: 26055067
[TBL] [Abstract][Full Text] [Related]
12. Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.
Ong KL; O'Connell R; Januszewski AS; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Waldman B; Colman PG; Best JD; Simes JR; Rye KA; Keech AC;
Clin Chem; 2017 Jul; 63(7):1261-1270. PubMed ID: 28606915
[TBL] [Abstract][Full Text] [Related]
13. Modifiable clinical and lifestyle factors are associated with elevated alanine aminotransferase levels in newly diagnosed type 2 diabetes patients: results from the nationwide DD2 study.
Mor A; Svensson E; Rungby J; Ulrichsen SP; Berencsi K; Nielsen JS; Stidsen JV; Friborg S; Brandslund I; Christiansen JS; Beck-Nielsen H; Sørensen HT; Thomsen RW
Diabetes Metab Res Rev; 2014 Nov; 30(8):707-15. PubMed ID: 24639417
[TBL] [Abstract][Full Text] [Related]
14. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.
Rajamani K; Colman PG; Li LP; Best JD; Voysey M; D'Emden MC; Laakso M; Baker JR; Keech AC;
Lancet; 2009 May; 373(9677):1780-8. PubMed ID: 19465233
[TBL] [Abstract][Full Text] [Related]
15. Alanine aminotransferase and mortality in patients with type 2 diabetes (ZODIAC-38).
Deetman PE; Alkhalaf A; Landman GW; Groenier KH; Kootstra-Ros JE; Navis G; Bilo HJ; Kleefstra N; Bakker SJ
Eur J Clin Invest; 2015 Aug; 45(8):807-14. PubMed ID: 26046667
[TBL] [Abstract][Full Text] [Related]
16. Γ-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men.
Wannamethee SG; Whincup PH; Shaper AG; Lennon L; Sattar N
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):830-5. PubMed ID: 22223732
[TBL] [Abstract][Full Text] [Related]
17. The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes.
Ford I; Mooijaart SP; Lloyd S; Murray HM; Westendorp RG; de Craen AJ; Packard CJ; Buckley B; Barlow C; Preiss D; Cobbe SM; Stott DJ; Sattar N
Int J Epidemiol; 2011 Dec; 40(6):1530-8. PubMed ID: 22158663
[TBL] [Abstract][Full Text] [Related]
18. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Scott R; O'Brien R; Fulcher G; Pardy C; D'Emden M; Tse D; Taskinen MR; Ehnholm C; Keech A;
Diabetes Care; 2009 Mar; 32(3):493-8. PubMed ID: 18984774
[TBL] [Abstract][Full Text] [Related]
19. Relation of Alanine Aminotransferase Levels to Cardiovascular Events and Statin Efficacy.
Harada PH; Cook NR; Cohen DE; Paynter NP; Rose L; Ridker PM
Am J Cardiol; 2016 Jul; 118(1):49-55. PubMed ID: 27317931
[TBL] [Abstract][Full Text] [Related]
20. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men.
Wannamethee SG; Shaper AG; Lennon L; Whincup PH
Diabetes Care; 2005 Dec; 28(12):2913-8. PubMed ID: 16306554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
